BeiGene (NASDAQ:BGNE) Shares Gap Down – Time to Sell?

BeiGene, Ltd. (NASDAQ:BGNE)’s share price gapped down prior to trading on Monday . The stock had previously closed at $236.10, but opened at $228.73. BeiGene shares last traded at $225.32, with a volume of 96,668 shares trading hands.

Analyst Ratings Changes

BGNE has been the topic of a number of recent analyst reports. Citigroup increased their price target on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. lifted their price target on shares of BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. JMP Securities began coverage on shares of BeiGene in a report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target for the company. Finally, Bank of America decreased their price objective on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a report on Tuesday, July 9th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $241.21.

BeiGene Trading Down 2.0 %

The company has a 50 day moving average of $205.15 and a 200 day moving average of $172.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. The stock has a market capitalization of $21.57 billion, a price-to-earnings ratio of -29.41 and a beta of 0.62.

BeiGene (NASDAQ:BGNE) last released its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. The business had revenue of $929.20 million during the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The company’s revenue for the quarter was up 56.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($3.64) earnings per share. On average, research analysts predict that BeiGene, Ltd. will post -5.07 EPS for the current fiscal year.

Insider Buying and Selling at BeiGene

In other news, CEO John Oyler sold 6,175 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO John Oyler sold 6,175 shares of the stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total value of $1,433,958.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $237.10, for a total value of $284,994.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,904 shares of company stock worth $5,034,965. Insiders own 7.43% of the company’s stock.

Institutional Investors Weigh In On BeiGene

Hedge funds have recently modified their holdings of the company. Headlands Technologies LLC acquired a new position in BeiGene in the 1st quarter valued at about $50,000. SG Americas Securities LLC acquired a new position in BeiGene in the third quarter valued at approximately $105,000. Benjamin F. Edwards & Company Inc. grew its position in BeiGene by 51.5% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock worth $128,000 after acquiring an additional 279 shares during the period. Acadian Asset Management LLC grew its position in BeiGene by 204.1% in the first quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after acquiring an additional 849 shares during the period. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in BeiGene during the first quarter worth $209,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.